Branch Retinal Vein Occlusion

Evaluation and management of branch retinal vein occlusion.

What is a Branch Retinal Vein Occlusion?

A branch retinal vein occlusion occurs when, because of hardening of the arteries, a branch retinal artery compresses a branch retinal vein causing blockage of the vein and decreased circulation in the distribution of that branch retinal vein. (see image) [note: the branch arteries are really arteriols and the branch veins are really veinules] There are several possible treatments for branch retinal vein occlusion including intravitreal injections, laser, and even surgery. Patients with BRVO lose vision for several reasons: poor circulation, hemorrhage and macular edema (swelling). There is no treatment, at the moment, to increase circulation or to remove hemorrhage. The macular edema, however, does respond well to intravitreal injections with Lucentis, Avastin, or steroids.

Read more

Lucentis for Branch Retinal Vein Occlusion

Monthly Lucentis therapy is also helpful in improving vision in patients with branch retinal vein occlusion and macular edema. Without treatment about 30 percent of have visual improvement. With treatment about 60 percent of patients have improved vision. Long term follow-up show that at 4 years, about half of the patients with branch retinal vein occlusion require continued treatment to maintain the visual benefit.


Eylea for Branch Retinal Vein Occlusion

Eylea was approved for treatment of branch retinal vein occlusion in late 2014. It is administered as an intravitreal injection monthly initially and then the treatment interval can be extended.


Branch Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Branch Retinal Vein Occlusion

2018-2023 Global Virtual Prototype Market Overview and Market Application  The Flatland Post

The Global Global Virtual Prototype Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023: Virtual Prototype Market Report ...

Retinal Vein Occlusion Market Rising Demand Seen in Healthcare at a CAGR of 11.2% by 2023 | By Types Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion – Says MRFR |  Medgadget

Market Research Future published a research report on “Global Retinal Vein Occlusion Market” to track and analyses developments which are competitive in.

Effect of intravitreal ranibizumab on serous retinal detachment in bra | OPTH  Dove Medical Press

Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion Emine Dogan,1 Ozkan Sever,2 Burcin Köklü Çakir,1 Erkan Celik1 ...

Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Could be Ready to Star in the Speculative Spotlight  FDA Headlines

Dec 7, 2018 | Business. Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Could be Ready to Star in the. Regeneron Pharmaceuticals Inc ...

Regeneron (REGN) Rides on Eylea and Dupixent's Performance  Zacks.com

Solid performance of approved drugs like Eylea and Dupixent along with an encouraging pipeline progress improve Regeneron's (REGN) market position.

Retinal Vein Occlusion Market Size and Trend by Branch and Central Retinal Vein Occlusion Type, Etc. Types and Forecast to 2023 |  Medgadget

Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients with glaucoma is leading the retinal vein ...

Retinal Vein Occlusion Market Leading Players - Allergan, Bayer, Bristol-Myers Squibb, Regeneron Pharmaceuticals & others, etc  openPR

Retinal Vein Occlusion Market Report Examines the Market position and viewpoint of the market globally, from various angles, such as key players, ...

Anti-VEGF treatment of macular edema associated with retinal vein occl | OPTH  Dove Medical Press

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2) J ...

First Republic Investment Management Inc. Reduces Stake in Regeneron Pharmaceuticals Inc (REGN)  Fairfield Current

First Republic Investment Management Inc. decreased its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 9.6% during the 3rd quarter, ...

Branch retinal vein occlusion (BRVO) recovery: Causes, symptoms, and treatment  Bel Marra Health

Branch retinal vein occlusion or BRVO is often referred to as an “eye stroke” and can impact a person's ability to see. The degree of vision loss varies in each ...

IOP spikes more likely after treatment in certain patients  Healio

Mild to moderate IOP spikes were seen after multiple injections of Ozurdex for treatment of uveitis, diabetic macular edema and retinal vein occlusion, but ...

Retinal Vein Occlusion Market 2018 Highlights | By Types – Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion | Top 10 Player Analysis by 2023 - Press Release  Digital Journal

Retinal Vein Occlusion Market Information: By Condition (Non-Ischemic and Ischemic), Diagnosis (Optical Coherence Tomography), Treatment and End-User ...

Mix of old and new sees ophthalmology updates! Flourish  Insight News

A unique formula and talented line-up of presenters has seen Ophthalmology Updates! go from strength-to-strength during its short history. In part two of his ...

Retinal Vein Occlusion (RVO) Market to Observe Strong Growth at a CAGR of 11.2% till 2023 | by MRFR |  Medgadget

Market Research Future (MRFR)'s study reveals that the “Global Retinal Vein Occlusion Market”, the report offer detailed Analysis about the Top Trends and.

Regeneron Pharmaceuticals (REGN) Stock Rating Upgraded by BidaskClub  Fairfield Current

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research ...

Comparison between intravitreal bevacizumab and posterior sub-tenon in | OPTH  Dove Medical Press

Comparison between intravitreal bevacizumab and posterior sub-tenon injection of triamcinolone acetonide in macular edema secondary to retinal vein ...

Ozurdex for retinal vein occlusion approved in China  Healio

The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein ...

Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $2.57 Million Holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)  Fairfield Current

Commonwealth of Pennsylvania Public School Empls Retrmt SYS cut its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 21.5% ...

Oppenheimer Reiterates $440.00 Price Target for Regeneron Pharmaceuticals (REGN)  Fairfield Current

Oppenheimer set a $440.00 target price on Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report released on Sunday morning. The firm currently ...

Safety, Tolerability Increases Post-Bevacizumab Injection in Intraocular Pressure  MD Magazine

New research has shown that increased IOP is tolerable to corneal endothelium, and safe for most patients' eyes despite immediate increases post-injection.

Intravitreal Diclofenac in the Treatment of Macular Edema Due to Branch Retinal Vein Occlusion  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE: To evaluate the effect of a single dose of intravitreal diclofenac on macular ...

Ozurdex® (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to retinal vein occlusion  Markets Insider

--An estimated 7.4 million people in China are living with this sight-threatening conditioni,ii,iii --. DUBLIN, March 22, 2018 /PRNewswire/ -- Today, Allergan plc ...

Regeneron Pharmaceuticals Inc (REGN) Expected to Post Earnings of $5.61 Per Share  Fairfield Current

Equities research analysts expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to post earnings per share of $5.61 for the current quarter, according to ...

Branch Retinal Artery Occlusion (BRAO): Causes, Symptoms, Diagnosis, and Treatment  Bel Marra Health

Branch retinal artery occlusion or BRAO is a vision-related disease-causing long-term vision problems. It is caused due to reduced or blocked blood flow.

Bayer files eye drug Eylea for new use in EU  PMLiVE

Bayer has filed an application to extend the indications of its ophthalmic drug Eylea in Europe to include use in patients with branch retinal vein occlusion ...

Young scientist helps identify cause of widespread eye disease  Science Daily

Branch retinal vein occlusion -- blockage of the blood vessels that channel blood from the retina -- is a common eye disease. A type of blood clot in the eye, the ...

NICE backs Bayer's Eylea as first-line BRVO treatment  PMLiVE

Bayer's Eylea (aflibercept) has been recommended for use on the NHS in England and Wales as a first-line treatment for adults with branch retinal vein ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Holdings Reduced by Commonwealth of Pennsylvania Public School Empls Retrmt SYS  Fairfield Current

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lessened its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by ...

FDA OKs Aflibercept (Eylea) for All Retinal Vein Occlusions  Medscape

The US Food and Drug Administration (FDA) has expanded the indication of aflibercept (Eylea, Regeneron) injection to include all forms of macular edema after ...

Surgical eye robot performs precision injection in patient with retinal vein occlusion  Medical Xpress

Eye surgeons at University Hospitals Leuven have been the first to use a surgical robot to operate on a patient with retinal vein occlusion. The robot uses a ...

Retinal Vein Occlusion Associated With Stroke  Medscape

Retinal vein occlusion (RVO) is significantly associated with stroke development, according to a recent study. Although the investigators adjusted for potential ...

RELATE study: Increased ranibizumab, laser yield minimal benefits  Healio

BOSTON — An increased dose of ranibizumab offered no added benefit in eyes with retinal vein occlusion, according to a study presented here. Additionally ...

Should We WAVE Goodbye to Laser?  Medscape

This study helps answer a common clinical question as to whether peripheral laser to areas of retinal ischemia improves vision and reduces injection burden in ...

Allergan's eye implant recalled due to foreign substance  Korea Biomedical Review

Allergan is recalling Ozurdex Intravitreal Implant 700㎍ (ingredient: dexamethasone), a steroid eye implant for macular edema, after detecting a foreign ...

Placenta Growth Factor Market 2018: Future Trends, Key Players: 123, Alteogen Inc., Chengdu Kanghong Pharmaceuticals Group Co Ltd, Clearside BioMedical, Inc., Formycon AG, Regeneron Pharmaceuticals Inc, ThromboGenics NV and more…  Industry Journal

Industrial Forecast on Placenta Growth Factor Market: A new report titled, “Global Placenta Growth Factor Market”, has been added by Reports Monitor to its vast ...

Retinal artery and vein thrombotic occlusion during pregnancy: markers | OPTH  Dove Medical Press

Retinal artery and vein thrombotic occlusion during pregnancy: markers for familial thrombophilia and adverse pregnancy outcomes Will S Kurtz,1 Charles J ...

Placenta Growth Factor Market Trends Analysis, Top Manufacturers, Shares, Growth  AlgosOnline

Global Placenta Growth Factor Market Forecast to 2025 released By Market Study Report provides Market information about industry Top Key Players, Countries ...

Altris.AI – The New Era of Retinal Diagnosis is Coming  Business Wire

Altris.AI (Altris, Inc) announced it has signed an agreement with a South Korean ophthalmic and optical medical equipment manufacturer Huvitz Co., Ltd.

Macular thickness differentiates occult BRAO, POAG  Healio

Macular scanning may be important in baseline glaucoma evaluation to differentiate occult branch retinal artery occlusion from primary open-angle glaucoma ...

Putnam FL Investment Management Co. Boosts Holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)  PressOracle

Putnam FL Investment Management Co. raised its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 1.6% in the 3rd quarter, according to ...

Placenta Growth Factor Market Research and Developments 2018 to 2025  Stetson Reporter

“Global Placenta Growth Factor Market Insights, Forecast To 2025” presents an in-depth assessment of the Placenta Growth Factor Market providing quantitative ...

Biosimilars Reported Safe, Effective for Retinal Disease  Medscape

CHICAGO — Biosimilars made in India are as safe and effective for retinal vascular diseases as the American-made originator drugs, but cost about 40% less, ...

Anti-VEGF Therapy Before Steroids for Retinal Vein Occlusion  Medscape

NICE, France — Aflibercept and ranibizumab are safer than dexamethasone intravitreal implants for the treatment of central retinal vein occlusion, a new study ...

Biosimilar Ranibizumab Effective in Treating RVO in a Real-World Setting  The Center for Biosimilars

In India, Razumab, manufactured by Intas Pharmaceuticals, was approved as a similar biologic to ranibizumab in 2015; the retrospective study RE-ENACT ...

Placenta Growth Factor Market Analysis by Current Industry Status & Growth Opportunities, Top Key Players, Target Audience and Forecast to 2025  The Flatland Post

The Placenta Growth Factor Market report analyses the competitive landscape read of the business. The Placenta Growth Factor report includes development ...

Disorganization of Retinal Inner Layers Linked to Visual Acuity Prognoses  MD Magazine

A new study suggests patients with disorganized retinal inner layers see lesser levels of visual acuity improvement after therapy.

Complications After Intravitreal Injection Aggravate  Medscape

VANCOUVER, Canada — Clusters of inflammatory responses after intravitreal injections have unnerved some specialists, who will share their experiences and ...

Retinal Vein Occlusion Therapeutics Market Share Worldwide Industry Growth, Size, Statistics, Opportunities & Forecasts up to 2023  News by Sharp Reports

An analysis of Retinal Vein Occlusion Therapeutics market has been provided in the latest report launched by Market Study Report that primarily focuses on the ...

Eye strokes (retinal artery occlusion): Symptoms, causes, and treatment  Bel Marra Health

Eye strokes can come one suddenly and result in partial or complete loss of vision. Learn about cause, risk factors and treatment options.

Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)  Business Wire

Genentech's investigational Port Delivery System with ranibizumab (PDS) is a small, refillable device, slightly longer than a grain of rice, surgically implanted in ...

Retina-AI releases AI mobile app for eye care providers  Healio

Retina-AI has released Fluid Intelligence, the first artificial intelligence mobile app for eye care providers, the company announced in a press release.

High systolic BP affects your retina and may lead to complete vision loss  Economic Times

Constant fluctuations in the systolic pressure can lead to many major eye complications.

Ready-to-Assemble Furniture Market 2018 Global Industry Share, Growth, Demand, Size, Revenue, Cost Structure and 2025 Forecast  The Future Gadgets

This report studies Placenta Growth Factor in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, ...

Risk Factors for Retinal Vein Occlusion  Medscape (subscription)

Is there a link between traditional risk factors for vascular disease and retinal vein occlusion?

Allergan Receives Approval for Ozurdex® (Dexamethasone Intravitreal Implant 0.7 mg) in China for the Treatment of Retinal Vein Occlusion (RVO)  PR Newswire

DUBLIN, Oct. 30, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today that it has received an Imported Drugs License (IDL) from the Chinese Food ...

Regeneron's Eylea Gets FDA Nod for Wet AMD as a 12-Week Dose  Zacks.com

Regeneron Pharmaceuticals (REGN) gets the FDA approval for the label expansion of its lead drug, Eylea as a treatment for wet AMD with a modified 12-week ...

Visual acuity loss associated with excessive "dry macula" in exudative | OPTH  Dove Medical Press

Visual acuity loss associated with excessive "dry macula" in exudative age-related macular degeneration Hidenori Takahashi,1–3 Yuji Inoue,1,2 Xue Tan,2,3 ...

FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy  PR Newswire

TARRYTOWN, N.Y., Sept. 13, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug ...

VEGF Inhibition Improves Visual Acuity in Macular Edema  Medscape

Ranibizumab improved visual acuity at 6 months in patients with macular edema secondary to ischemic branch retinal vein occlusion, whether or not they ...

Evaluation of microvascular changes in the macular area of eyes with r | OPTH  Dove Medical Press

Yuji Yoshikawa, Takuhei Shoji, Junji Kanno, Hisashi Ibuki, Kimitake Ozaki, Hirokazu Ishii, Yoshikazu Ichikawa, Itaru Kimura, Kei Shinoda Department of ...

Aflibercept Injections Superior to Laser for Macular Edema  Medscape

Intravitreal injections of aflibercept were more effective than laser therapy for the treatment of macular edema secondary to branch retinal vein occlusion, ...

Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:To evaluate the effects of squalamine (OHR-102; Ohr Pharmaceuticals, ...

Regeneron Gains on Eylea, Dupixent and Pipeline Progress  Nasdaq

Shares of Regeneron Pharmaceuticals Inc . REGN have gained 3.2% in the year so far against a decline of 5.9% for the industry . Tarrytown,.

Visual Prognosis of Branch Retinal Artery Occlusion  Medscape (subscription)

What is the relationship between initial visual acuity and visual prognosis in patients with branch retinal artery occlusion (BRAO)?

Retinal Vein Occlusion Market expected to grow at a CAGR of 11.2% By 2023  openPR

Market Research Future Recently Added Premium Research Reports on ” Retinal Vein Occlusion Market Research Report - Global Forecast till 2023” Which ...

Laser Speckle Flowgraphy Can Assist in CRVO Prognosis  Medscape

Laser speckle flowgraphy may offer a noninvasive method of assessing ocular blood flow in patients with central retinal vein occlusion (CRVO), according to a ...

Global Placenta Growth Factor Market 2018 | Top Players Strategic Analysis, Market Dynamics, Restraints, and Growth Forecast 2018 – 2023  Ask Reporter 24

QYresearch.us presents Global Placenta Growth Factor Market 2018 industry research report that covers overall business insights and forecast.

New Stairway Study Data Shows Potential for Extended Durability with Faricimab in Wet Age-Related Macular Degeneration (AMD)  Business Wire

Faricimab – the first bispecific antibody designed for the eye – dosed every four months demonstrated sustained vision outcomes compared to monthly ...

Ophthalmic Suspension Market Comprehensive Study 2018: Novartis, ALLERGAN, Pfizer, Merck, Valeant Pharmaceuticals, Bayer, Genentech, Falcon Group, Ciron Drugs And Pharmaceuticals Private Limited, DOLVIS BIO PHARMA PRIVATE LIMITED, Entod, UBM, FDC Limited  openPR

Ophthalmic Suspension market report is a respected source of information which offers a telescopic view of the current market status. Various key factors are ...

Regeneron (REGN) to Report Q3 Earnings: Is a Beat in Store?  Zacks.com

Investors' focus will be on the company's performance, particularly on Eylea and Dupixient's uptake during Regeneron's (REGN) third-quarter earnings call.

Global Placenta Growth Factor Market Analysis 2018-2025  positivesource24.com

International Placenta Growth Factor Market report Insights, the research report presents a complete assessment of Placenta Growth Factor industry's new ...

Similar Efficacy for Key Anti-VEGF Agents in Macular Edema  Medscape

The SCORE2 trial shows that bevacizumab and aflibercept may produce similar short-term outcomes. Here is a closer look at its results.

Fast Action Can Save Sight if Retina Is Detached or Blocked  New York Times

Modern treatments can do wonders if they are begun before the damage to the eye is irreversible.

Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?  Nasdaq

Regeneron Pharmaceuticals, Inc . REGN is scheduled to release second-quarter 2018 results on Aug 2, before the opening bell. In the last reported.

Ophthalmic Suspension Market Booming With Novartis, ALLERGAN, Pfizer, Merck, Valeant Pharmaceuticals, Bayer, Genentech, Falcon Group, Ciron Drugs And Pharmaceuticals Private Limited, DOLVIS BIO PHARMA PRIVATE LIMITED, PDA-Parenteral Drug Association  openPR

Global market study” Ophthalmic Suspension Market” in-depth Research of the Healthcare Industry state and the competitive landscape globally. It analyses the ...

Ozurdex approved for treatment of macular edema  Monthly Prescribing Reference

Allergan's Ozurdex (dexamethasone intravitreal implant) has been approved by the FDA for the treatment of macular edema following branch retinal vein ...

RETINA-AI Releases the First Artificial Intelligence Mobile App for Eye-Care Providers: Fluid Intelligence by RETINA-AI  PR Newswire

HOUSTON, July 17, 2018 /PRNewswire/ -- RETINA-AI has developed and released the first Artificial Intelligence mobile app for eye-care providers. This app ...

FDA Approves Genentech's Lucentis (ranibizumab injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy  Business Wire

First and only prefilled syringe treatment option FDA-approved to treat all forms of diabetic retinopathy in people with or without diabetic macular edema (DME) ...

Regeneron's sBLA for Eylea Accepted by FDA, Action Date Set  Nasdaq

Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has accepted for review the company's supplemental Biologics License Application (sBLA).

Steroid Injections May Help Restore Vision In Some Patients With Blocked Eye Veins  Science Daily (press release)

Injecting the eye with the corticosteroid triamcinolone appears effective in improving the vision of some patients with retinal vein occlusion, an important cause of ...

Retinal Vein Occlusion Market 2023 Top Key Players are Allergan, Bayer, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Ellex Medical Lasers, GlaxoSmithKline Plc, IRIDEX Corporation, Novartis  openPR

Market Research Future Recently Added Premium Research Reports on ” Retinal Vein Occlusion Market Research Report - Global Forecast till 2023” Which ...

Ranibizumab Outperforms Aflibercept in Efficacy, Durability  MD Magazine

According to the interim results of the RIVAL trial, ranibizumab (Lucentis) showed an increase of 2.2 more letters compared to aflibercept.

The eye jab that can banish blind spots  Daily Mail

Clive Woodington had Central Retinal Vein Occlusion (CRVO), a distressing condition that can lead to blindness in the affected eye.

Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Duplixant Data Came at Just the Right Time  FDA Headlines

Oct 16, 2018 | Business. Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Duplixant Data Came at Just the Right. Regeneron Pharmaceuticals Inc ...

New data comparing Lucentis efficacy and durability versus aflibercept  The Pharma Letter

Swiss pharma giant Novartis (NOVN: VX) today reported new data from a Phase IV head-to-head study (RIVAL) confirming Lucentis (ranibizumab) efficacy and ...

Perfluorocarbon liquid-assisted intraocular foreign body removal | OPTH  Dove Medical Press

Perfluorocarbon liquid-assisted intraocular foreign body removal Cindy Ung, Inês Laíns, Thanos D Papakostas, Safa Rahmani, John B Miller Retina *Service*, ...

Image processing algorithm shows promise for mapping the blood vessel networks in the eye  Phys.Org

More accurate and efficient mapping of retinal blood vessels using a path-following image processing scheme, developed by an A*STAR-led research team, ...

Monthly, PRN doses of ranibizumab similarly effective in RVO  Healio

TORONTO — As-needed and monthly ranibizumab dosing regimens yielded similar visual acuity gains in patients with retinal vein occlusion who reached a ...

Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People With Diabetic Macular Edema  Business Wire

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced encouraging results from the Phase II BOULEVARD study.

RETINA-AI Releases Android Version of Fluid-Intelligence -- World's First Mobile Artificial Intelligence App for Eye Care Providers  PR Newswire

HOUSTON, Oct. 22, 2018 /PRNewswire/ -- RETINA-AI has released an Android version of its app Fluid-Intelligence, the world's first mobile artificial intelligence ...

Retinal Thinning Linked To Neural Loss In Parkinson's Disease  ReliaWire

Thinning of the retina, the lining of nerve cells in the back of the eye, is linked to the loss of brain cells that produce dopamine, a new study has found. “Our study ...

FDA OKs Ozurdex for Some With Diabetic Macular Edema  Medscape

The new indication is for treatment of adults with diabetic macular edema who have an artificial lens implant (pseudophakic) or who are scheduled for cataract ...

Bayer's Eylea cleared for wider use in Europe  PMLiVE

Bayer's eye disease therapy Eylea has been cleared for a new macular oedema indication in the EU, stepping up competition against rival therapy Lucentis from ...

Regeneron Eylea Hits 24-Week Primary Endpoint in Study  Nasdaq

Regeneron Pharmaceuticals, Inc. REGN announced positive topline results from the phase III study evaluating Eylea (aflibercept) Injection in moderately severe ...

Bayer receives approval for Eylea in China  The FINANCIAL

The FINANCIAL -- Bayer announced on May 11 that Eylea (aflibercept solution for injection into the eye) has been approved by the Chinese regulatory ...

CRAO and Stroke Risk: Is Neurological Evaluation Warranted?  Medscape

Patients with central retinal artery occlusion may be at an increased risk for stroke and may benefit from prompt neurological evaluation, according to a new ...

NICE gives Bayer's Elyea a provisional 'no' for first-line use  PMLiVE

The National Institute of Health and Care Excellence (NICE) is poised to hand Bayer's Eylea a limited recommendation for the treatment of branch retinal vein ...

Treatment of refractory uveitic macular edema: results of a first and | OPTH  Dove Medical Press

Marta Zola, Cristina Briamonte, Umberto Lorenzi, Federica Machetta, Federico M Grignolo, Antonio M Fea Ophthalmic Eye Hospital, Department of Surgical ...

NICE nod for new Eylea indication  PharmaTimes

The National Institute for Health and Care Excellence (NICE) has issued a final positive recommendation for Bayer's Eylea as a treatment for adults for the ...

IRIS Registry Finds New AMD, DME Population Data  MD Magazine

Studies based on data from the world's largest clinical specialty database corrected commonly-perceived trends in ophthalmology.

» Load more